US › Healthcare

Milestone Pharmaceuticals Inc (MIST)

US · Healthcare · Biotechnology

$0.92+3.42%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$559,000

Net profit

$-28.6M

EPS

$-0.21

EPS estimate

$-0.18

Net margin

-5,118.8%

EPS came in at -0.21 against a street estimate of -0.18 — a miss of 16.7%.

Key statistics

Market cap

$130.7M

Forward P/E

0.0

P/B

7.35

Book value

$0.13

EPS (TTM)

$-0.64

52-week high

$3.06

52-week low

$1.00

50-day MA

$1.18

200-day MA

$1.65

Beta

0.98

Analyst view

Analysts rate Milestone Pharmaceuticals Inc a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $5.86.

Shareholding

Insiders

0.70%

Institutions

50.57%

Largest institutional holders

Fund	Stake
Propel Bio Management LLC	5.97%
RTW INVESTMENTS, LLC	5.09%
Simplify Asset Management Inc.	2.69%
Millennium Management LLC	2.52%
Two Sigma Investments LLC	1.86%
The Goldman Sachs Group Inc	1.61%
Marshall Wace Asset Management Ltd	1.56%
Point72 Asset Management, L.P.	0.87%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Milestone Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.